Number of the records: 1
Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular crcinoma conversion therapy: a prospecitve, single-arm phase II trial
- LIU, Dongming. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular crcinoma conversion therapy: a prospecitve, single-arm phase II trial. In Neoplasma. ISSN 0028-2685. Bratislava : AEPress, 2023, 2023, vol. 70, no. 6, s. 811-818.
Number of the records: 1